Use access key #2 to skip to page content.
$2.41 0.02 (0.84%)
7/3/2008 1:00 PM

Cell Genesys, Inc. (CEGE)

CAPS Rating:
***

A biotechnology company focused on the development and commercialization of novel biological therapies for patients with cancer.

View All Commentary (CEGE)

Recs

0

Avatar Money2themax (93.98) Submitted: 5/07/08 12:28 AM : Underperform Start Price: $3.74 CEGE Score: 24.54

IF full FDA approval happens for the cancer-fighting drug that is currently in Stage III Trials, this stock launches and never looks back! However, FDA approval timing is unpredictable so look for this stock to be in the doldrums for awhile yet.

Report this Post Replies: 1 | Reply

Avatar nordm (81.44) Submitted: 5/11/08 12:15 AM

Recs: 0 | Rec This

Agreed, however I think you've mis-appraised the 'doldrums' price level. Your start price is it for me. The recent move up was not about anticipating FDA approval (still 18 months out at least). It moved up because of the $320M deal with Takeda, $50M is already in the bank, they will get another $20M over the remainder of 2008, and the balance over the course of the next couple of years. If and when approval happens, this will be trading many times higher than the current price. Until then... the doldrums.

Report this Post Reply

Featured Broker Partners